- Home
- SLG vs IBRX Comparison
SLG vs IBRX Comparison
Compare SLG & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLG | IBRX |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | SLG | IBRX |
|---|---|---|
| Price | $48.73 | $5.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 4 |
| Target Price | ★ $55.24 | $11.50 |
| AVG Volume (30 Days) | 1.1M | ★ 26.5M |
| Earning Date | 01-28-2026 | 03-02-2026 |
| Dividend Yield | ★ 6.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $661,814,000.00 | $82,555,000.00 |
| Revenue This Year | N/A | $667.58 |
| Revenue Next Year | $7.17 | $92.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1025.95 |
| 52 Week Low | $40.26 | $1.83 |
| 52 Week High | $68.14 | $5.58 |
Technical Indicators
Market Signals| Indicator | SLG | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.59 | 92.86 |
| Support Level | $47.43 | $1.95 |
| Resistance Level | $49.85 | $2.29 |
| Average True Range (ATR) | 1.53 | 0.28 |
| MACD | 0.23 | 0.30 |
| Stochastic Oscillator | 74.46 | 98.48 |
Price Performance
Historical ComparisonAbout SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.